Open AccessComparative study of esomeprazole and lansoprazole in triple therapy for eradication ofHelicobacter pyloriin Japan
Author(s) -
Tsutomu Nishida,
Masahiko Tsujii,
H Tanimura,
Shusaku Tsutsui,
S. Tsuji,
Atsushi Takeda,
Akira Inoue,
Hirokazu Fukui,
Toshiyuki Yoshio,
Osamu Kishida,
Hiroyuki Ogawa,
Masahide Oshita,
Ichizo Kobayashi,
Shinichiro Zushi,
Makoto Ichiba,
Naoto Uenoyama,
Yuichi Yasunaga,
Ryu Ishihara,
Mamoru Yura,
Masato Komori,
Satoshi Egawa,
Hideki Iijima,
Tetsuo Takehara
Publication year - 2014
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v20.i15.4362
Subject(s) - lansoprazole , esomeprazole , helicobacter pylori , medicine , clarithromycin , gastroenterology , amoxicillin , pharmacotherapy , intention to treat analysis , combination therapy , urea breath test , randomized controlled trial , helicobacter pylori infection , antibiotics , microbiology and biotechnology , biology
To evaluate the efficacy and safety of esomeprazole-based triple therapy compared with lansoprazole therapy as first-line eradication therapy for patients with Helicobacter pylori (H. pylori) in usual post-marketing use in Japan, where the clarithromycin (CAM) resistance rate is 30%.